2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
270股Bio股價因百時美施貴寶合作的癌症免疫療法的積極數據而上漲
- Bristol Myers Squibb Co (NYSE:BMY) and 2seventy bio Inc (NASDAQ:TSVT) have announced topline results from KarMMa-3 Phase 3 trial of Abecma (idecabtagene vicleucel) for multiple myeloma.
- The trial compared Abecma to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen.
- The interim analysis demonstrated a statistically significant improvement in progression-free survival.
- Related Content: Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
- Treatment with Abecma also showed an improvement in the key secondary endpoint of overall response rate compared to standard regimens.
- Follow-up for overall survival, a key secondary endpoint, remains ongoing.
- No new safety signals were reported in this study.
- The FDA approved Abecma in March 2021 for relapsed or refractory multiple myeloma after four or more prior lines of therapy.
- Abecma generated $72 million as U.S. commercial revenue in 2Q, split evenly between 2seventy and BMS.
- 2seventy said it is on track toward the upper end of $250-$300M revenue guidance for 2022.
- TSVT ended the June quarter with $399 million in cash. It revised 2022 net cash spend to $245-265 million with a cash runway into 2025.
- Price Action: TSVT shares are up 10.80% at $18.50 during the premarket session on the last check Wednesday.
- Bristol Myers Squibb Co (NYSE:BMY) and 2seventy bio Inc (NASDAQ:TSVT) have announced topline results from KarMMa-3 Phase 3 trial of Abecma (idecabtagene vicleucel) for multiple myeloma.
- The trial compared Abecma to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen.
- The interim analysis demonstrated a statistically significant improvement in progression-free survival.
- Related Content: Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
- Treatment with Abecma also showed an improvement in the key secondary endpoint of overall response rate compared to standard regimens.
- Follow-up for overall survival, a key secondary endpoint, remains ongoing.
- No new safety signals were reported in this study.
- The FDA approved Abecma in March 2021 for relapsed or refractory multiple myeloma after four or more prior lines of therapy.
- Abecma generated $72 million as U.S. commercial revenue in 2Q, split evenly between 2seventy and BMS.
- 2seventy said it is on track toward the upper end of $250-$300M revenue guidance for 2022.
- TSVT ended the June quarter with $399 million in cash. It revised 2022 net cash spend to $245-265 million with a cash runway into 2025.
- Price Action: TSVT shares are up 10.80% at $18.50 during the premarket session on the last check Wednesday.
- 百時美施貴寶公司(紐約證券交易所代碼：BMY)和270 Bio Inc.納斯達克公司(Temasek Holdings：TSVT)宣佈了Abecma(依達卡他汀)治療多發性骨髓瘤的KarMma-3期3期試驗的主要結果。
- 這項試驗比較了Abecma與標準聯合療法在成人復發和難治性多發性骨髓瘤患者中的作用，這些患者在之前的兩到四個系列治療後，對最後一個方案無效。
- 中期分析顯示，無進展存活率在統計學上有顯著改善。
- 相關內容： 百時美施貴寶，270拔下多個骨髓瘤CAR-T的插頭，Abecma銷售勢頭增強
- 與標準方案相比，使用Abecma的治療還顯示總應答率的關鍵次要終點有所改善。
- 作為一個關鍵的次要終點，總存活率的後續行動仍在進行中。
- 在這項研究中沒有新的安全信號報道。
- FDA於2021年3月批准Abecma用於復發或難治性多發性骨髓瘤，此前曾接受過四種或四種以上的治療。
- Abecma在第二季度創造了7200萬美元的美國商業收入，在270和BMS之間平均分配。
- 270表示，它正朝着2022年2.5億至3億美元營收指引的上限邁進。
- 截至6月底的季度，TSVT的現金為3.99億美元。該公司將2022年的淨現金支出修正為2.45億至2.65億美元，並將現金轉移到2025年。
- 價格行動：在週三最後一次檢查的盤前交易中，TSVT股價上漲10.80%，至18.50美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！